Dexlansoprazole injection - Jiangsu Aosaikang Pharmaceutical

Drug Profile

Dexlansoprazole injection - Jiangsu Aosaikang Pharmaceutical

Latest Information Update: 21 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jiangsu Aosaikang Pharmaceutical
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Pyridines; Small molecules; Sulfoxides
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Erosive oesophagitis; Gastro-oesophageal reflux

Most Recent Events

  • 14 Apr 2017 Zhejiang University and Jiangsu Aosaikang Pharmaceutical initiate enrolment in a phase I trial in Healthy volunteers in China (NCT03120273)
  • 09 Mar 2017 Jiangsu Aosaikang Pharmaceutical completes a phase I trial in Gastro-oesophageal reflux and Erosive oesophagitis (In volunteers) in China (NCT03011125)
  • 01 Jan 2017 Phase-I clinical trials in Erosive oesophagitis (In volunteers) in China (IV) (NCT03011125)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top